8/3, 12:26 PM (Source: TeleTrader)
more TeleTrader news

Eli Lilly's EPS slip 1% to $1.53 in Q2

Eli Lilly and Company revealed on Tuesday that its diluted earnings per share (EPS) declined by 1% compared to the same period a year prior, to stand at $1.53 in the second fiscal quarter of 2021.

The company's revenue soared 23% during the same period, climbing to $6.74 billion, while net income decreased 2% on a yearly basis to land at $1.39 billion in the second trimester. Excluding COVID-19-related sales, the firm's revenue surged 12% on an annual level.

"We delivered strong performance this quarter, with volume-driven growth across our core business and most major geographies. We accelerated use of our newest medicines around the world with solid sequential growth versus first-quarter 2021," Eli Lilly CEO David Ricks noted.

Breaking the News / BU